- Home
- PIII vs ICU Comparison
PIII vs ICU Comparison
Compare PIII & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- ICU
- Stock Information
- Founded
- PIII 2015
- ICU 2018
- Country
- PIII United States
- ICU United States
- Employees
- PIII N/A
- ICU N/A
- Industry
- PIII Medical/Nursing Services
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- ICU Health Care
- Exchange
- PIII Nasdaq
- ICU Nasdaq
- Market Cap
- PIII 28.6M
- ICU 25.6M
- IPO Year
- PIII N/A
- ICU N/A
- Fundamental
- Price
- PIII $8.78
- ICU $0.84
- Analyst Decision
- PIII Strong Buy
- ICU
- Analyst Count
- PIII 3
- ICU 0
- Target Price
- PIII $17.50
- ICU N/A
- AVG Volume (30 Days)
- PIII 7.0K
- ICU 1.4M
- Earning Date
- PIII 08-14-2025
- ICU 08-13-2025
- Dividend Yield
- PIII N/A
- ICU N/A
- EPS Growth
- PIII N/A
- ICU N/A
- EPS
- PIII N/A
- ICU N/A
- Revenue
- PIII $1,461,823,000.00
- ICU $766,000.00
- Revenue This Year
- PIII N/A
- ICU $894.81
- Revenue Next Year
- PIII $9.46
- ICU $71.78
- P/E Ratio
- PIII N/A
- ICU N/A
- Revenue Growth
- PIII 4.20
- ICU N/A
- 52 Week Low
- PIII $5.80
- ICU $0.31
- 52 Week High
- PIII $29.19
- ICU $5.79
- Technical
- Relative Strength Index (RSI)
- PIII 72.18
- ICU 51.78
- Support Level
- PIII $8.08
- ICU $0.79
- Resistance Level
- PIII $8.93
- ICU $0.92
- Average True Range (ATR)
- PIII 0.45
- ICU 0.07
- MACD
- PIII 0.13
- ICU -0.01
- Stochastic Oscillator
- PIII 93.61
- ICU 39.89
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.